(Adnkronos) - "Una efficacia mai vista in studi precedenti che si è mantenuta per quasi 2 anni”. Così, Carlo Pozzilli, professore ordinario dipartimento di Neuroscienze Umane, Università La Sapienza e direttore Centro Sclerosi multipla, Ospedale S. Andrea di Roma, commenta i risultati dell’impiego di ravulizumab per il trattamento del disturbo dello spettro della neuromielite ottica (Nmosd) in occasione dell’incontro con Astrazeneca, Alexion - AstraZeneca Rare Disease in cui è stata annunciata la rimborsabilità, da parte di Aifa, dell’anticorpo monoclonale per gli adulti con la patologia e positivi all'anticorpo anti-aquaporina-4 (Aqp4) (Ab+).
Category
🗞
NewsTranscript
00:00What is the role of the Shampion study?
00:04The Shampion study is a study that has used a drug called Ravolizumab,
00:09which is a monoclonal antibody that acts directly on the complement fraction 5.
00:15So it is an innovative mechanism of action compared to other drugs that were used in the past,
00:21which acted more like immunosuppressants,
00:24and therefore also creating problems of infections or oncogenic risks.
00:29This is a drug that has proven to be effective, I must say, in previous studies.
00:35I had the good fortune to experiment on patients with this drug
00:39and to be able to see that none of the patients studied in the trial
00:44in the period of almost two years had relapsed.
00:48Now we also have a greater follow-up, which is about two and a half years.
00:52The data was recently presented at a conference in Canada
00:57and I must say that this effectiveness has been maintained over time.
01:02It is a drug that is administered for endovenous reasons every two months,
01:08thus also facilitating the convenience of the patient
01:13compared to similar drugs that were injected every 15 days.